FDA Approves Novartis’ Mayzent for Relapsing Forms of Multiple Sclerosis, Including Active SPMS

The FDA has announced approval of the oral drug, Mayzent (siponimod) for the treatment of clinically isolated syndrome, relapsing-remitting MS as well as for active secondary progressive MS. Mayzent (siponimod) comes from the same family of drugs as Gilenya (fingolimod), however Mayzent binds to more specific receptors in the body. This means that we believe this new drug will be just as effective as Gilenya but should have fewer side effects and adverse reactions. Mayzent should be available to prescribe over the next few months so patients can discuss Mayzent with their neurologist at their next office visit.

CLICK HERE for the announcement from the FDA

News Date : 
Thursday, March 28, 2019 (All day)


Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.